ReviewCurrent opinion in pharmacology2014
The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease.
Review in Current opinion in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review.International journal of chronic obstructive pulmonary disease · 2017Pooled it
- Genomic crosstalk between carbachol, a muscarinic receptor agonist, and the long-acting βThe Journal of pharmacology and experimental therapeutics · 2025Article
- Anti-carcinogenic effects of arecaidine but-2-ynyl ester tosylate on breast cancer: proliferation inhibition and activation of apoptosis.Molecular biology reports · 2025Article
- β-Adrenergic Receptor Antagonism of Cholinergic Stimulation of Airway Smooth Muscle Contraction: An Old Receptor Requires a Fresh Look.Function (Oxford, England) · 2023Article
- Inhibition of neurogenic contractions in renal arteries and of cholinergic contractions in coronary arteries by the presumed inhibitor of ADP-ribosylation factor 6, NAV2729.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- Does coupling to ADP ribosylation factor 6 explain differences between muscarinic and other receptors in interaction with β-adrenoceptor-mediated smooth muscle relaxation?Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Inhibition of Human Prostate and Bladder Smooth Muscle Contraction, Vasoconstriction of Porcine Renal and Coronary Arteries, and Growth-Related Functions of Prostate Stromal Cells by Presumed Small Molecule GαFrontiers in physiology · 2022Article
- Survivin knockdown alleviates pathological hydrostatic pressure-induced bladder smooth muscle cell dysfunction and BOO-induced bladder remodelingFrontiers in cell and developmental biology · 2022Article
- Role of Airway Smooth Muscle in Inflammation Related to Asthma and COPD.Advances in experimental medicine and biology · 2021Article
- βBritish journal of pharmacology · 2019Review
- Urinary Bladder Weight and Function in a Rat Model of Mild Hyperglycemia and Its Treatment With Dapagliflozin.Frontiers in pharmacology · 2019Article
- Involvement of Allosteric Effect and KInternational journal of molecular sciences · 2018Article
- Selective inhibition of histamine-evoked CaCell calcium · 2018Article
- Inhaled therapies in patients with moderate COPD in clinical practice: current thinking.International journal of chronic obstructive pulmonary disease · 2018Review
- Structure-Based Design and Discovery of New MJournal of medicinal chemistry · 2017Article
- Drugs Interfering with Muscarinic Acetylcholine Receptors and Their Effects on Place Navigation.Frontiers in psychiatry · 2017Review
- Involvement of CaInternational journal of molecular sciences · 2016Article
- Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.International journal of chronic obstructive pulmonary disease · 2016Article
- β3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase.Naunyn-Schmiedeberg's archives of pharmacology · 2015Article
- Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.International journal of chronic obstructive pulmonary disease · 2015Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
Muscarinic receptor antagonists and β-adrenoceptor agonists are used in the treatment of obstructive airway disease and overactive bladder syndrome. Here we review the pharmacological rationale for their combination. Muscarinic receptors and β-adrenoceptors are physiological antagonists for smooth muscle tone in airways and bladder. Muscarinic agonism may attenuate β-adrenoceptor-mediated relaxation more than other contractile stimuli. Chronic treatment with one drug class may regulate expression of the target receptor but also that of the opposing receptor. Prejunctional β2-adrenoceptors can enhance neuronal acetylcholine release. Moreover, at least in the airways, muscarinic receptors and β-adrenoceptors are expressed in different locations, indicating that only a combined modulation of both systems may cause dilatation along the entire bronchial tree. While all of these factors contribute to a rationale for a combination of muscarinic receptor antagonists and β-adrenoceptor agonists, the full value of such combination as compared to monotherapy can only be determined in clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.